High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients

International Journal of Cancer

Volumn 134, Issue 10, 2014, Pages 2352-2358

  Sokolenko, Anna P ^a,b   Bulanova, Daria R ^c   Iyevleva, Aglaya G ^a,b   Aleksakhina, Svetlana N ^a   Preobrazhenskaya, Elena V ^a   Ivantsov, Alexandr O ^a   Kuligina, Ekatherina Sh ^a   Mitiushkina, Natalia V ^a   Suspitsin, Evgeny N ^a   Yanus, Grigoriy A ^a,b   Zaitseva, Olga A ^a   Yatsuk, Olga S ^a   Togo, Alexandr V ^a   Kota, Poojitha ^c   Dixon, J Michael ^d   Larionov, Alexey A ^d,e   Kuznetsov, Sergey G ^c   Imyanitov, Evgeny N ^a,b,f  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

Author keywords

BRCA1; breast cancer; genetic predisposition; GPRC5A

Indexed keywords

BRCA1 PROTEIN; G PROTEIN COUPLED RECEPTOR; SMALL INTERFERING RNA;

ALLELE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GPRC5A GENE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ONCOGENE; PREVALENCE; PRIORITY JOURNAL; TRANSLATION REGULATION; TUMOR SUPPRESSOR GENE;

BRCA1; BREAST CANCER; GENETIC PREDISPOSITION; GPRC5A;

ADULT; AGED; BRCA1 PROTEIN; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DNA REPAIR; EXOME; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; MUTATION; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84895919811     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28569     Document Type: Article

References (42)

1. Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011; 12: 745-55.
2. Gilissen C, Hoischen A, Brunner HG, et al. Disease gene identification strategies for exome sequencing. Eur J Hum Genet 2012; 20: 490-7.
3. Simard J, Dumont M, Soucy P, et al. Perspective: prostate cancer susceptibility genes. Endocrinology 2002; 143: 2029-40.
4. Chen S, Parmigiani G,. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-33.
5. Barnes DR, Antoniou AC,. Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers. J Intern Med 2012; 271: 331-43.
6. Lalloo F, Evans DG,. Familial breast cancer. Clin Genet 2012; 82: 105-14.
7. Njiaju UO, Olopade OI,. Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. Breast J 2012; 18: 436-42.
8. Ellis NA, Offit K,. Heterozygous mutations in DNA repair genes and hereditary breast cancer: a question of power. PLoS Genet 2012; 8: e1003008.
9. O'Daniel JM, Lee K,. Whole-genome and whole-exome sequencing in hereditary cancer: impact on genetic testing and counseling. Cancer J 2012; 18: 287-92.
10. Abbott A,. Manhattan versus Reykjavik. Nature 2000; 406: 340-2.
11. Neuhausen SL,. Founder populations and their uses for breast cancer genetics. Breast Cancer Res 2000; 2: 77-81.
12. Sokolenko AP, Mitiushkina NV, Buslov KG, et al. High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur J Cancer 2006; 42: 1380-4.
13. Suspitsin EN, Sherina NY, Ponomariova DN, et al. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients. Hered Cancer Clin Pract 2009; 7: 5.
14. Iyevleva AG, Suspitsin EN, Kroeze K, et al. Non-founder BRCA1 mutations in Russian breast cancer patients. Cancer Lett 2010; 298: 258-63.
15. Sokolenko AP, Iyevleva AG, Preobrazhenskaya EV, et al. High prevalence and breast cancer predisposing role of the BLM c1642 C>T (Q548X) mutation in Russia. Int J Cancer 2012; 130: 2867-73.
16. Thompson ER, Doyle MA, Ryland GL, et al. Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet 2012; 8: e1002894.
17. Prokofyeva D, Bogdanova N, Dubrowinskaja N, et al. Nonsense mutation pQ548X in BLM, the gene mutated in Bloom's syndrome, is associated with breast cancer in Slavic populations. Breast Cancer Res Treat 2013; 137: 533-9.
18. Suspitsin EN, Sokolenko AP, Voskresenskiy DA, et al. Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier. Breast Cancer 2011; 18: 137-40.
19. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25: 402-8.
20. Cheng Y, Lotan R,. Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor. J Biol Chem 1998; 273: 35008-15.
21. Tao Q, Fujimoto J, Men T, et al. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst 2007; 99: 1668-82.
22. Moran A, O'Hara C, Khan S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 2012; 11: 235-42.
23. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812-22.
24. Holliday DL, Speirs V,. Choosing the right cell line for breast cancer research. Breast Cancer Res 2011; 13: 215.
25. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-27.
26. Zhong Q, Chen CF, Li S, et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 1999; 285: 747-50.
27. King TA, Li W, Brogi E, et al. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol 2007; 14: 2510-18.
28. Palacios J, Robles-Frías MJ, Castilla MA, et al. The molecular pathology of hereditary breast cancer. Pathobiology 2008; 75: 85-94.
29. Kadara H, Fujimoto J, Men T, et al. A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia 2010; 12: 499-505.
30. Deng J, Fujimoto J, Ye XF, et al. Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila) 2010; 3: 424-37.
31. Fujimoto J, Kadara H, Men T, et al. Comparative functional genomics analysis of NNK tobacco-carcinogen induced lung adenocarcinoma development in Gprc5a-knockout mice. PLoS One 2010; 5: e11847.
32. Barta P, Van Pelt C, Men T, et al. Enhancement of lung tumorigenesis in a Gprc5a Knockout mouse by chronic extrinsic airway inflammation. Mol Cancer 2012; 11: 4.
33. Nagahata T, Sato T, Tomura A, et al. Identification of RAI3 as a therapeutic target for breast cancer. Endocr Relat Cancer 2005; 12: 65-73.
34. Wu Q, Ding W, Mirza A, et al. Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target. J Biol Chem 2005; 280: 12935-43.
35. Hirano M, Zang L, Oka T, et al. Novel reciprocal regulation of cAMP signaling and apoptosis by orphan G-protein-coupled receptor GPRC5A gene expression. Biochem Biophys Res Commun 2006; 351: 185-91.
36. Jörissen H, Bektas N, Dahl E, et al. Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer. BMC Cancer 2009; 9: 200.
37. Dairkee SH, Sayeed A, Luciani G, et al. Immutable functional attributes of histologic grade revealed by context-independent gene expression in primary breast cancer cells. Cancer Res 2009; 69: 7826-34.
38. Hofmann WK, de Vos S, Komor M, et al. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002; 100: 3553-60.
39. Zougman A, Hutchins GG, Cairns DA, et al. Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker. Eur J Cancer 2013; 49: 531-9.
40. Cheng L, Yang S, Yang Y, et al. Global gene expression and functional network analysis of gastric cancer identify extended pathway maps and GPRC5A as a potential biomarker. Cancer Lett 2009; 29: 105-13.
41. Konishi H, Mohseni M, Tamaki A, et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci USA 2011; 108: 17773-8.
42. Couch FJ, Wang X, McGuffog L, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 2013; 9: e1003212.